REFERENCES
1. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32-50.
2. Rinella ME, Lazarus JV, Ratziu V, et al. ; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
3. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9.
4. GBD 2023 MASLD Collaborators. Global burden of metabolic dysfunction-associated steatotic liver disease, 1990-2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Gastroenterol Hepatol. 2026;11:463-94.
5. Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697-707.
6. Celsa C, Pennisi G, Tulone A, et al. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10:998-1012.
7. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691-702.
8. Wilson MP, Singh R, Mehta S, Murad MH, Fung C, Low G. Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE thresholds and diagnostic accuracies for detecting hepatic fibrosis in patients with MASLD: a systematic review and meta-analysis. Diagnostics. 2025;15:1598.
9. Dawod S, Brown K. Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. Front Med. 2024;11:1499013.
10. Lai JC, Liang LY, Wong GL. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Gastroenterol Rep 2024;12:goae024.
11. Fichez J, Mouillot T, Vonghia L, et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials. JHEP Rep. 2025;7:101351.
12. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
13. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
14. Amini-Salehi E, Letafatkar N, Norouzi N, et al. Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries. Arch Med Res. 2024;55:103043.
15. Cao L, An Y, Liu H, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. BMC Med. 2024;22:101.
16. Grocic M, Nguyen M, Sanyal AJ. Current trends in the epidemiology of obesity and the association between obesity and metabolic liver disease (MASLD/MASH). Diabetes Obes Metab. 2026;28:3-18.
17. Bae JH. Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: a call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: a longitudinal real-world study”. Clin Mol Hepatol. 2024;30:665-8.
18. Rich NE, Oji S, Mufti AR, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198-210.e2.
19. Sato-Espinoza K, Chotiprasidhi P, Huaman MR, Díaz-Ferrer J. Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol. 2024;16:452-64.
20. Ramírez-Mejía MM, Díaz-Orozco LE, Barranco-Fragoso B, Méndez-Sánchez N. A review of the increasing prevalence of metabolic-associated fatty liver disease (MAFLD) in children and adolescents worldwide and in mexico and the implications for public health. Med Sci Monit. 2021;27:e934134.
21. Lefere S, Koot BGP, Mann JP, Bufler P, De Bruyne R, Hudert CA. Update in clinical science: MASLD in children and adolescents. J Hepatol. 2026;84:1164-77.
22. Cheah MCC, Crane H, George J. Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis. Hepatol Int. 2025;19:607-18.
23. Cherubini A, Della Torre S, Pelusi S, Valenti L. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease. Trends Mol Med. 2024;30:1126-36.
24. Jamalinia M, Saeian S, Nikkhoo N, Nazerian A, Lankarani KB. Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions. Metab Target Organ Damage 2025;5:60.
25. Eng PC, Forlano R, Tan T, Manousou P, Dhillo WS, Izzi-Engbeaya C. Non-alcoholic fatty liver disease in women - current knowledge and emerging concepts. JHEP Rep. 2023;5:100835.
26. Truong XT, Lee DH. Hepatic insulin resistance and steatosis in metabolic dysfunction-associated steatotic liver disease: new insights into mechanisms and clinical implications. Diabetes Metab J. 2025;49:964-86.
27. Dua A, Kumari R, Singh M, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes. Front Med. 2025;12:1618275.
28. Ma J, Ma Y, Wan X, et al. Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges. Front Endocrinol. 2025;16:1639064.
29. Lorek D, Łupina K, Bisaga W, et al. The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes. Korean J Fam Med. 2025;46:61-9.
30. Singh V, Cheng S, Velazquez A, Trivedi HD, Kwan AC. The impact of social determinants of health on metabolic dysfunction-associated steatotic liver disease among adults in the United States. J Clin Med. 2025;14:5484.
31. Kanda T, Sasaki-Tanaka R, Abe H, et al. Polygenic risk score for metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a narrative review. Int J Mol Sci. 2025;26:5164.
32. Pei Y, Goh GB. Genetic risk factors for metabolic dysfunction-associated steatotic liver disease. Gut Liver. 2025;19:8-18.
33. Kozlitina J, Sookoian S. Global epidemiological impact of PNPLA3 I148M on liver disease. Liver Int. 2025;45:e16123.
34. Karapanagiotidi F, Boutari C, Sinakos E. Genetic predisposition to MASLD: potential for therapeutic management. Int J Mol Sci. 2026;27:1933.
35. Benedé-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD). Gut Microbes. 2024;16:2331460.
36. Schnabl B, Damman CJ, Carr RM. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. J Clin Invest. 2025;135:e186423.
37. Ramírez-Mejía MM, Ponciano-Rodríguez G, Méndez-Sánchez N. Implications of the liver-gut axis in liver disease: from mechanisms to therapeutic targets. Arch Med Res. 2025;56:103335.
38. García S, Monserrat-Mesquida M, Ugarriza L, et al. Ultra-processed food consumption and metabolic-dysfunction-associated steatotic liver disease (MASLD): a longitudinal and sustainable analysis. Nutrients. 2025;17:472.
39. Geladari EV, Kounatidis D, Christodoulatos GS, et al. Ultra-processed foods and metabolic dysfunction-associated steatotic liver disease (MASLD): what is the evidence so far? Nutrients 2025;17:2098.
40. Li X, Li J, Zhou J, et al. Mapping the association between environmental pollutants and steatotic liver disease: a systematic review and meta-analysis. Environ Res. 2025;285:122623.
41. Ran S, Zhang J, Tian F, et al. Association of metabolic signatures of air pollution with MASLD: observational and Mendelian randomization study. J Hepatol. 2025;82:560-70.
42. Zhao Y, He H, Zeng J, Zhang J. Environmental endocrine-disrupting chemicals and metabolic dysfunction-associated steatotic liver disease. Liver Int. 2026;46:e70793.
43. Ghosh S, Nukavarapu SP, Jala VR. Effects of heavy metals on gut barrier integrity and gut microbiota. Microbiota and Host. 2023;2:e230015.
44. Wei G, Liu W, Shen F, et al. Polystyrene microplastics exposure increases the disruption of intestinal barrier integrity and gut microbiota homeostasis during obesity and aging. J Environ Sci. 2026;162:430-43.
45. Gao B, Arab JP, Liangpunsakul S, et al. Metabolic dysfunction and alcohol-associated liver disease (MetALD). eGastroenterology. 2025;3:e100319.
46. Acierno C, Barletta F, Caturano A, et al. Alcohol consumption and liver metabolism in the era of MASLD: integrating nutritional and pathophysiological insights. Nutrients. 2025;17:2229.
48. Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23:117.
49. Ramírez-Mejía MM, Qi X, Abenavoli L, Romero-Gómez M, Eslam M, Méndez-Sánchez N. Metabolic dysfunction: the silenced connection with fatty liver disease. Ann Hepatol. 2023;28:101138.
50. Hagström H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9:944-56.
52. Huang DQ, Tran S, Barnett S, et al. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study. Hepatol Int. 2024;18:540-9.
53. Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3-10.
54. Le P, Payne JY, Zhang L, et al. Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies. Clin Gastroenterol Hepatol. 2023;21:1154-68.
55. Sierra L, Liu L, Khurana A, et al. Reversing fibrosis in metabolic dysfunction-associated steatohepatitis-beyond telling patients to lose weight. Cleve Clin J Med. 2026;93:279-86.
56. Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265-73.
57. Gancheva S, Roden M, Castera L. Diabetes as a risk factor for MASH progression. Diabetes Res Clin Pract. 2024;217:111846.
58. Martínez-Sánchez FD, Corredor-Nassar MJ, Feria-Agudelo SM, et al. Factors associated with advanced liver fibrosis in a population with type 2 diabetes: a multicentric study in Mexico city. J Clin Exp Hepatol. 2025;15:102536.
59. Julián MT, Arteaga I, Torán-Monserrat P, et al. The link between abdominal obesity indices and the progression of liver fibrosis: insights from a population-based study. Nutrients. 2024;16:1586.
60. Krawczyk M, Rau M, Schattenberg JM, et al. ; NAFLD Clinical Study Group. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res. 2017;58:247-55.
61. Mustafa A, Kite C, Lagojda L, et al. Cardiovascular disease in the context of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive narrative review. Int J Mol Sci. 2025;26:11275.
62. Lazarus JV, Mark HE, Anstee QM, et al. ; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60-78.
63. Phoolchund AGS, Khakoo SI. MASLD and the development of HCC: pathogenesis and therapeutic challenges. Cancers. 2024;16:259.
64. Mi K, Ye T, Zhu L, Pan CQ. Risk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD. Gastroenterol Rep. 2025;13:goaf018.
65. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223-38.
66. Rodriguez LA, Schmittdiel JA, Liu L, et al. Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease. JAMA Netw Open. 2024;7:e2421019.
67. Shenoy A, Ahmed A, Kim D. Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease. Metab Target Organ Damage. 2025;5:46.
68. Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50:101506.
69. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70:962-9.
70. Córdova-Gallardo CJ, Vargas-Beltran AM, Ramírez Mejía MM, Méndez-Sánchez N. MASLD as a multisystemic disease. In: Méndez-Sánchez N, Qi X, Editors. Metabolic dysfunction-associated steatotic liver disease: prevalence, research insights and the future directions. Singapore: Springer Nature Singapore; 2024. pp. 87-94. Available from https://link.springer.com/book/10.1007/978-981-97-9519-2. [accessed 26 August 2026].
71. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082-90.
72. Cao YT, Xiang LL, Qi F, Zhang YJ, Chen Y, Zhou XQ. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. EClinicalMedicine. 2022;51:101547.
73. Zhang YX, Feng YP, You CL, Zhang LY. The diagnostic value of MRI-PDFF in hepatic steatosis of patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25:451.
74. Indre MG, Leucuta DC, Lupsor-Platon M, et al. Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: a multilevel random effects model meta-analysis. Hepatology. 2025;82:454-69.
75. Han S, Choi M, Lee B, et al. Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gut Liver. 2022;16:952-63.
76. López Tórrez SM, Ayala CO, Ruggiro PB, et al. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants. Front Nutr. 2024;11:1284509.
77. Hinkson A, Lally H, Gibson H, et al. Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol Ther. 2023;57:750-62.
78. Eslam M, Wong GL, Hashem AM, et al. A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients. Am J Gastroenterol. 2021;116:984-93.
79. Canivet CM, Zheng MH, Qadri S, et al. Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic nonalcoholic steatohepatitis: an international study with 1924 patients. Clin Gastroenterol Hepatol. 2023;21:3097-106.e10.
80. Malandris K, Arampidis D, Mainou M, et al. FibroScan-AST score for diagnosing fibrotic MASH: a systematic review and meta-analysis of diagnostic test accuracy studies. J Gastroenterol Hepatol. 2024;39:2582-91.
81. Liu S, Zhang Q, Wang L, Tang Q, Hu B. MAST versus FAST for active fibrotic MASH: a meta-analysis supporting risk-stratified diagnostic pathways. Front Med. 2026;13:1779292.
82. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive Summary. Diabetologia. 2024;67:2375-92.
83. Portincasa P, Khalil M, Mahdi L, et al. Metabolic dysfunction-associated steatotic liver disease: from pathogenesis to current therapeutic options. Int J Mol Sci. 2024;25:5640.
84. Petroff D, Blank V, Newsome PN, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:185-98.
85. Alsaqal S, Hockings P, Ahlström H, et al. The combination of MR elastography and proton density fat fraction improves diagnosis of nonalcoholic steatohepatitis. J Magn Reson Imaging. 2022;56:368-79.
86. Qu Y, Middleton MS, Loomba R, et al. Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosis. Eur Radiol. 2021;31:8408-19.
87. Lee DH. Quantitative assessment of fatty liver using ultrasound attenuation imaging. J Med Ultrason. 2021;48:465-70.
88. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112:740-51.
89. Sung S, Al-Karaghouli M, Tam M, et al. Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care. Hepatol Commun. 2025;9:e0609.
90. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013;59:236-42.
91. Eslam M, Fan JG, Yu ML, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025;19:261-301.
92. Tsochatzis EA, Valenti L, Thiele M, et al. Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: a qualitative exploration of challenges and barriers. Liver Int. 2024;44:1990-2001.
93. Yeramaneni S, Chang ST, Cheung RC, et al. Comparison of referral rates and costs using fibrosis-4 and enhanced liver fibrosis (ELF) testing strategies for initial evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) in a veteran population. J Appl Lab Med. 2025;10:593-604.
94. Li Q, Gao Y, Wang D, et al. Prospective comparison of 2D-shear wave elastography and vibration-controlled transient elastography in assessing liver fibrosis in metabolic dysfunction-associated steatotic liver disease. Acad Radiol. 2025;32:5100-11.
95. Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016;26:1431-40.
96. Kawanaka M, Kamada Y, Takahashi H, et al. ; Japan Study Group of NAFLD (JSG-NAFLD). Serum cytokeratin 18 fragment is an indicator for treating metabolic dysfunction-associated steatotic liver disease. Gastro Hep Adv. 2024;3:1120-8.
97. Boursier J, Anty R, Vonghia L, et al. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther. 2018;47:1387-96.
98. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362-73.
99. Truong E, Gornbein JA, Yang JD, et al. MRI-AST (MAST) score accurately predicts major adverse liver outcome, hepatocellular carcinoma, liver transplant, and liver-related death. Clin Gastroenterol Hepatol. 2023;21:2570-7.e1.
100. Noureddin M, Truong E, Gornbein JA, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol. 2022;76:781-7.
101. Jamialahmadi O, De Vincentis A, Tavaglione F, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3614-23.
102. Xiao L, Li Y, Hong C, et al. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes. J Transl Med. 2024;22:650.
103. Tobaruela-Resola AL, Milagro FI, Mogna-Pelaez P, Moreno-Aliaga MJ, Abete I, Zulet MÁ. The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD. J Physiol Biochem. 2025;81:589-609.
104. Tobaruela-Resola AL, Milagro FI, Elorz M, et al. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for metabolic dysfunction-associated steatotic liver disease assessment. J Physiol Biochem. 2025;81:1275-88.
105. Thiele M, Villesen IF, Niu L, et al. ; MicrobLiver consortium, GALAXY consortium. Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases. J Hepatol. 2024;81:345-59.
106. Boel F, Akimov V, Teuchler M, et al. Deep proteome profiling of metabolic dysfunction-associated steatotic liver disease. Commun Med. 2025;5:56.
107. Verschuren L, Mak AL, van Koppen A, et al. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. Nat Commun. 2024;15:4564.
108. Tan EY, Muthiah MD, Sanyal AJ. Metabolomics at the cutting edge of risk prediction of MASLD. Cell Rep Med. 2024;5:101853.
109. Schneider KM, Cao F, Huang HYR, et al. The lipidomic profile discriminates between MASLD and MetALD. Aliment Pharmacol Ther. 2025;61:1357-71.
110. Ning M, Lu D, Liang D, Ren PG. Single-cell RNA sequencing advances in revealing the development and progression of MASH: the identifications and interactions of non-parenchymal cells. Front Mol Biosci. 2025;12:1513993.
111. Li JZ, Yang L, Xiao MX, et al. Spatial and single-cell transcriptomics reveals the regional division of the spatial structure of MASH fibrosis. Liver Int. 2025;45:e16125.
112. Watson BR, Paul B, Rahman RU, et al. Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution. Nat Commun. 2025;16:319.
113. Li Z, Luo G, Gan C, et al. Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease. Nat Genet. 2025;57:3112-25.
114. Zhou XD, Li YT, Kim SU, et al. ; VCTE-Prognosis Study Group, Paired Liver Biopsy Group. Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in MASLD. Clin Gastroenterol Hepatol. 2026;24:394-406.
115. Vettor R, Petroni ML, Dotan I, et al. Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Rev Endocr Metab Disord. 2026;27:213-35.
116. Mathur A, Ozkaya E, Rosberger S, et al. Concordance of vibration-controlled transient elastography and magnetic resonance elastography for fibrosis staging in patients with metabolic dysfunction-associated steatotic liver disease. Eur Radiol. 2025;35:6507-15.
117. Borz-Baba L, Aydin A, Parvin R. Liver biopsy in metabolic-associated steatotic liver disease: accuracy, challenges, and alternatives. Cureus. 2026;18:e103284.
118. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. ; Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76:959-74.
119. Lei SY, Han Y, Rockey DC, et al. ; International Obesity Society Working Group on Steatotic Liver Disease. An international multidisciplinary consensus statement on laparoscopic liver biopsy. Cell Rep Med. 2026;7:102831.
120. Lonardo A, Ballestri S, Mantovani A, Targher G, Bril F. Endpoints in NASH clinical trials: are we blind in one eye? Metabolites 2024;14:40.
121. Turan Gokce D, Ekelik M, Gumussoy M, et al. Histological disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy. Eur J Gastroenterol Hepatol. 2026;38:76-81.
122. Ratziu V, Hompesch M, Petitjean M, et al. Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. J Hepatol. 2024;80:335-51.
123. Kleiner DE, Brunt EM, Wilson LA, et al. ; Nonalcoholic Steatohepatitis Clinical Research Network. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2:e1912565.
124. Nascimbeni F, Bedossa P, Fedchuk L, et al. ; LIDO (Liver Injury in Diabetes and Obesity) Study Group. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol. 2020;72:828-38.
125. Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. Liver Int. 2024;44:1762-7.
126. Arab JP, Díaz LA, Rehm J, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82:744-56.
127. Grüner Nielsen D, Andersen K, Søgaard Nielsen A, Juhl C, Mellentin A. Consistency between self-reported alcohol consumption and biological markers among patients with alcohol use disorder - a systematic review. Neurosci Biobehav Rev. 2021;124:370-85.
128. Rady ED, Cotter TG. Integrating phosphatidylethanol to enhance alcohol quantification in steatotic liver disease and clinical trials. Liver Int. 2026;46:e70489.
129. Tavaglione F, Díaz LA, Ajmera V, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol. 2025;83:1023-34.
130. Vaz J, Nasr P, Helander A, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025;83:1011-22.
131. Loomba R, Hagström H, Díaz LA. Emerging role of phosphatidylethanol testing in clinical practice for the identification of steatotic liver disease subtypes: is this the new standard? Gastroenterology 2025;169:1103-7.
132. Vaz J, Hagström H. Reply to: “Why one PEth result cannot redraw the MASLD/ALD boundary: a single-snapshot misclassification” and “Phosphatidylethanol-guided reclassification of steatotic liver disease subgroups improves prognostic stratification: greater precision is required”: phosphatidylethanol in steatotic liver disease: real-world evidence. J Hepatol. 2025;83:e234-5.
133. Tampaki M, Tsochatzis E, Lekakis V, Cholongitas E. Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease (MetALD): a systematic review and meta-analysis. Metabolism. 2025;163:156101.
134. Méndez-Sánchez N, Brouwer WP, Lammert F, Yilmaz Y. Metabolic dysfunction associated fatty liver disease in healthy weight individuals. Hepatol Int. 2024;18:884-96.
135. Ramírez-Mejía MM, Qi X, Abenavoli L, Méndez-Sánchez N. The myth of the stigma of fatty liver: what does the evidence show? Ann Hepatol 2024;29:101535.
136. Dunn N, Verma N, Dunn W. Artificial intelligence for predictive diagnostics, prognosis, and decision support in MASLD, hepatocellular carcinoma, and digital pathology. J Clin Exp Hepatol. 2026;16:103184.
137. Kanwal F, Shubrook JH, Younossi Z, et al. Preparing for the NASH epidemic: a call to action. Metabolism. 2021;122:154822.
138. Hernández-Almonacid PG, Marín-Quintero X. Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: transforming diagnosis and therapeutic approaches. World J Gastroenterol. 2026;32:111737.
139. Barbhuiya PA, Ahmed A, Pathak MP. Advancing metabolic dysfunction associated steatotic liver disease (MASLD) treatment: exploring novel formulations and therapies. J Drug Deliv Sci Technol. 2026;115:107702.
